USB Piper downgraded MedImmune (MEDI) to outperform.
Analyst Mark Schoenebaum says he hadn't expected Wal-mart's decision to not offer the FluMist vaccination in stores this year. He says the news dents his thesis that FluMist sales will significantly beat the Street's expectations this year. As a result, he lowered the five million 2003 dose estimate to four million.
Schoenebaum says he downgraded MedImmune to outperform from strong buy; he maintains a positive rating because he continues to believe that the earnings power of FluMist has been significantly underestimated by the Street, and that peak FluMist doses will approach 20 million. He thinks the product will fuel 23% earnings per share growth over the next three to five years. Schoenebaum has a $42 target.